Acceleron Pharma Stock Price, News & Analysis (NASDAQ:XLRN)

Acceleron Pharma trades on the NASDAQ under the ticker symbol "XLRN."

Acceleron Pharma Inc (NASDAQ:XLRN) issued its earnings results on Monday, August, 5th. The biopharmaceutical company reported ($0.34) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.24) by $0.10. The biopharmaceutical company earned $27.67 million during the quarter, compared to analyst estimates of $28.72 million. Acceleron Pharma had a negative return on equity of 29.51% and a negative net margin of 318.84%. Acceleron Pharma's quarterly revenue was up 649.9% on a year-over-year basis. During the same period in the prior year, the business earned ($0.63) earnings per share. View Acceleron Pharma's Earnings History.

Acceleron Pharma is scheduled to release their next quarterly earnings announcement on Tuesday, October 29th 2019. View Earnings Estimates for Acceleron Pharma.

12 brokerages have issued 1-year target prices for Acceleron Pharma's stock. Their predictions range from $45.00 to $78.00. On average, they anticipate Acceleron Pharma's stock price to reach $59.3636 in the next twelve months. This suggests a possible upside of 37.7% from the stock's current price. View Analyst Price Targets for Acceleron Pharma.

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Acceleron Pharma in the last year. There are currently 3 hold ratings and 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Acceleron Pharma.

Media coverage about XLRN stock has been trending somewhat negative recently, InfoTrie Sentiment reports. The research group rates the sentiment of media coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Acceleron Pharma earned a coverage optimism score of -1.3 on InfoTrie's scale. They also assigned media coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View News Stories for Acceleron Pharma.

Some companies that are related to Acceleron Pharma include Qiagen (QGEN), BIO-TECHNE (TECH), bluebird bio (BLUE), Moderna (MRNA), Adaptive Biotechnologies (ADPT), argenx (ARGX), Repligen (RGEN), China Biologic Products (CBPO), Spark Therapeutics (ONCE), Allogene Therapeutics (ALLO), Ablynx (ABLYF), Crispr Therapeutics (CRSP), Iovance Biotherapeutics (IOVA), Halozyme Therapeutics (HALO) and Denali Therapeutics (DNLI).

Based on aggregate information from My MarketBeat watchlists, some companies that other Acceleron Pharma investors own include Bristol-Myers Squibb (BMY), Gilead Sciences (Gild), Incyte (Incy), LogicBio Therapeutics (LOGC), Corcept Therapeutics (CORT), Bausch Health Companies (BHC), FibroGen (FGEN), Intercept Pharmaceuticals (ICPT), Celgene (Celg) and Cisco Systems (CSCO).

Acceleron Pharma's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (9.34%), Vanguard Group Inc. (7.76%), Price T Rowe Associates Inc. MD (7.16%), Artal Group S.A. (2.85%), Janus Henderson Group PLC (2.49%) and Janus Henderson Group PLC (2.49%). Company insiders that own Acceleron Pharma stock include Adam M Veness, Christopher Rovaldi, Corp /De/ Celgene, Habib J Dable, Jean George, John D Quisel, Joseph S Zakrzewski, Kevin F Mclaughlin, Matthew L Sherman, Ravindra Kumar and Richard F Pops. View Institutional Ownership Trends for Acceleron Pharma.

XLRN stock was sold by a variety of institutional investors in the last quarter, including Price T Rowe Associates Inc. MD, Artal Group S.A., Marshall Wace North America L.P., Westfield Capital Management Co. LP, Novo Holdings A S, Tiverton Asset Management LLC, Amundi Pioneer Asset Management Inc. and Bank of America Corp DE. Company insiders that have sold Acceleron Pharma company stock in the last year include Adam M Veness, Habib J Dable, Jean George, John D Quisel, Kevin F Mclaughlin and Ravindra Kumar. View Insider Buying and Selling for Acceleron Pharma.

XLRN stock was purchased by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Sofinnova Investments Inc., Nuveen Asset Management LLC, Candriam Luxembourg S.C.A., BlackRock Inc., Bamco Inc. NY, Vanguard Group Inc. and AXA. Company insiders that have bought Acceleron Pharma stock in the last two years include Corp /De/ Celgene and Joseph S Zakrzewski. View Insider Buying and Selling for Acceleron Pharma.

Shares of XLRN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of XLRN stock can currently be purchased for approximately $43.10.

Acceleron Pharma has a market capitalization of $2.27 billion and generates $13.99 million in revenue each year. The biopharmaceutical company earns $-118,870,000.00 in net income (profit) each year or ($2.59) on an earnings per share basis. Acceleron Pharma employs 173 workers across the globe.View Additional Information About Acceleron Pharma.

The official website for Acceleron Pharma is http://www.acceleronpharma.com/.

Acceleron Pharma's mailing address is 128 SYDNEY STREET, CAMBRIDGE MA, 02139. The biopharmaceutical company can be reached via phone at 617-649-9200 or via email at [email protected]